Press Releases
- Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care
- Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care
- Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care
- Actavis plc is now Allergan plc
- Bert Vogelstein, M.D., Wins 2015 Dr. Paul Janssen Award for Biomedical Research
- More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.

